Number of the records: 1
Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study
- 1.
SYSNO ASEP 0565982 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational study Author(s) Wasserbauer, M. (CZ)
Hlava, S. (CZ)
Trojánek, M. (CZ)
Šťovíček, J. (CZ)
Milota, T. (CZ)
Drábek, J. (CZ)
Koptová, P. (CZ)
Cupková, A. (CZ)
Pichlerová, D. (CZ)
Kučerová, B. (CZ)
Coufal, Štěpán (MBU-M) ORCID, RID
Keil, R. (CZ)Number of authors 12 Article number e0273612 Source Title PLoS ONE. - : Public Library of Science - ISSN 1932-6203
Roč. 17, č. 9 (2022)Number of pages 15 s. Language eng - English Country US - United States Keywords COVID-19 ; infections Subject RIV EC - Immunology OECD category Immunology Method of publishing Open access Institutional support MBU-M - RVO:61388971 UT WOS 000892641400025 EID SCOPUS 85137154655 DOI 10.1371/journal.pone.0273612 Annotation Background and aims
SARS-CoV-2 is a worldwide serious health problem and vaccination seems to have a crucial role in managing the COVID-19 pandemic. The aim of this prospective observational study was to monitor the trend of antibodies against SARS-CoV-2 after vaccination with BNT162b2 (COMIRNATY) in patients with inflammatory bowel disease treated by immunosuppressive and/or biological therapy, demonstrate whether any type of this therapy is associated with poorer production of antibodies against COVID-19 and evaluate the safety of vaccination against COVID-19 in these patients.
Methods
Eighty-seven eligible patients from one tertiary gastroenterological center with inflammatory bowel disease (60 with CD, 27 with UC) treated by immunosuppressive and/or biological therapy from the antiTNF alpha group were indicated to vaccination against SARS-CoV-2. Effectiveness of vaccination was evaluated by the values of antibodies before and 4 weeks after 2nd dose of vaccine. Additional goal was to evaluate adverse events of vaccination.
Results
Before the 2nd dose of vaccine, geometric mean of SARS-CoV-2 IgG antibodies were 40.7 U/ml in the biological therapy group, 34.8 U/ml in the azathioprine group and 44.8 U/ml in the combination therapy group of patients. The geometric means were 676.5.7 U/ml in the biological therapy group, 614.4 U/ml in the azathioprine group and 500.1 U/mI in the combination therapy group of patients four weeks after 2nd dose. Statistically significant ferences between these groups were not proved. Several non-severe local and general adverse events were present in our patients with a majority of these events on the day of vaccine administration and the day after, no anaphylactic reactions were present.
Conclusions
Our measurements proved the efficacy and safety of vaccination against SARS-CoV-2 in patients with inflammatory bowel disease treated by immunosuppressive and/or biological therapy.Workplace Institute of Microbiology Contact Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231 Year of Publishing 2023 Electronic address https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0273612
Number of the records: 1